A few studies demonstrated that in patients with myelofibrosis who received ruxolitinib [10] or navtemadlin (a MDM2 inhibitor) [14] circulating CD34-positive cells decreases progressively during treatment. This evidence concerns the gene CD34 and myelofibrosis.